Navigation Links
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Date:8/19/2007

looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the potential for CoFactor to receive regulatory approval for metastatic colorectal cancer or other indications on a timely basis or at all; the uncertain process of seeking regulatory approval; difficulties or delays in developing, testing, manufacturing and marketing of CoFactor; the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; the ability to timely enroll subjects in ADVENTRX's current and anticipated clinical trials; the timing and success of clinical trials; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; adverse side effects or inadequate therapeutic efficacy of CoFactor; the risk that preclinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical and clinical data suggest or as otherwise anticipated; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)
2. Adventrx Announces Positive Data From Multidrug Therapy With CoFactor
3. ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/5hkm2f/medical_oxygen ) has ... - Global Strategic Business Report" report to their ... for Medical Oxygen Systems in US$ Thousands by the ... & Regulators, and Oxygen Conserving Devices. The report provides ... , Japan , ...
(Date:4/17/2015)... 17, 2015 Steven Rash , the CEO ... its operating subsidiary American Seed & Oil Company, presented ... investors yesterday in New York City.  Mr. Rash,s presentation ... American Seed & Oil Company has recently announced the ... Hemp Seed Foods , the EpiVape , and ...
(Date:4/17/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/7qs3dw/corporate ) has ... Pharma in 2014 - a Perspective of Diabetes Patient ... This independent study, funded by the author, ... interest in diabetes on the corporate reputation of 14 ... a whole) in 2014. The results from the respondent ...
Breaking Medicine Technology:Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5
... & NEW DELHI, India--(BUSINESS WIRE)--Jun 21, 2007,- The ... today announced that Phase 3 research,related to its ... published in the current issue of The,New England ... the medicine paromomycin is safe, effective, and well ...
... MRSA,in Healthcare Facilities, WASHINGTON, June 21, 2007 /PRNewswire-USNewswire/ -- The,following ... WHAT:, -- First nationwide study of the ... aureus (MRSA), a virulent multi-drug resistant organism, ... -- MRSA prevalence study findings significantly exceed previous estimates, ...
Cached Medicine Technology:Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 2Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 3Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 4Nationwide MRSA Prevalence Study to Demonstrate Full Scope of,'Superbug' Threat Facing U.S. Healthcare Facilities and Patients 2
(Date:4/17/2015)... April 17, 2015 “We have seen healing, ... the past and present,” said Chaplain Shawn Kafader of Friendship ... felt like they had anything to contribute have created beautiful ... overseen a new art therapy program that was launched to ... Masters student from School of the Art Institute in Chicago, ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive Director ... April 15th, the European Parliament joined its voice with ... Armenian Genocide, “paying tribute, on the eve of the ... Armenian victims who perished in the Ottoman Empire.” ... this timely and needed recognition of a tragic episode ...
(Date:4/17/2015)... DC (PRWEB) April 17, 2015 Representatives ... HHT Diagnoses and Treatment Act HR 1849 in congress ... diagnosis rates and treatment for patients with the genetic ... in the past, would be the first to create ... and appropriate treatment of hereditary hemorrhagic telangiectasia. This would ...
(Date:4/17/2015)... Hills, California (PRWEB) April 17, 2015 ... stands above in his new offering of platelet-rich plasma ... Orthopedic Sports Medicine (MOSM) is known for its ... Dr. Meier brings extensive surgical experience lacking in many ... and stem cell treatments are utilized for pain management ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Most dental ... dental restoration units are made overseas by foreign dental ... domestic labs remain unregulated in more than 40 states ... National Association of Dental Laboratories has created ... raise awareness among patients about the consequences that could ...
Breaking Medicine News(10 mins):Health News:Healing At Friendship Village Due To Art Therapy 2Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2
... TORONTO, Nov. 12 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.,("Transition" or ... hold a,conference call on Wednesday, November 14, 2007 at ... financial results. Dr. Tony Cruz, Chairman,and Chief Executive Officer ... its financial results for this period in a press ...
... Incorporated,(Nasdaq: VPHM ) today announced that the ... Medicines Agency (EMEA) has granted orphan,drug designation for ... patients with impaired cell-mediated immunity. The EMEA,s,"Orphan Medicinal ... drugs which may provide significant benefit to patients,suffering ...
... spirometry to clinical exams benefits those with symptoms , MONDAY, ... diagnosing and treating the lung illness known as stable ... American College of Physicians (ACP). , COPD, typically caused ... affects more than 5 percent of American adults and is ...
... Now has,selected its $7,500 Grand Prize winner in its ... walks away with the big prize,after a 3-month competition ... will receive $250 in the contest. The winning video ... "Brendan Hayward captured, in just 30 seconds, what ...
... Mich., Nov. 12 Leading health care risk,management ... third,quarter results for the period ended Sept. 30, ... quarter and first nine months of the year. ... medical,professional liability insurance and integrated risk management products,and ...
... Medical,Association (AMA) proudly presented Portland physician Richard Allen, ... its semi-annual,policy-making meeting. Dr. Allen is the first ... for meritorious service in the science and art,of ... advancing medical education," said,AMA President Ron Davis, M.D. ...
Cached Medicine News:Health News:Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2008 Financial Results on Wednesday, November 14, at 8:30 A.M. EST 2Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 2Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 3Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 4Health News:New Guideline Targets Treatment of Stable COPD 2Health News:Psoriasis Cure Now Video Contest $7,500 Grand Prize Winner Announced 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 3Health News:Portland Physician Wins AMA Distinguished Service Award 2
... The PipetBoy Pipettor is light as a feather ... aspiration speed can be continuously adjusted. The pipette ... be autoclaved. Two dosing knobs enable fine dosing ... plastic an/or glass pipettes from 0.1 to 100 ...
Precise, safe, and fatigue-free series pipetting using graduated pip...
Inquire...
Inquire...
Medicine Products: